TY - JOUR
T1 - Complications, Symptoms, Presurgical Predictors in Patients With Chronic Hypoparathyroidism
T2 - A Systematic Review
AU - Yao, Liang
AU - Hui, Xu
AU - Li, Meixuan
AU - Li, Jing
AU - Ahmed, Muhammad Muneeb
AU - Lin, Clement
AU - Kandi, Maryam
AU - Sreekanta, Ashwini
AU - Makhdami, Nima
AU - Tamilselvan, Divya
AU - Ali, Dalal S.
AU - Dandurand, Karel
AU - Yang, Kehu
AU - Bilezikian, John P.
AU - Brandi, Maria Luisa
AU - Clarke, Bart L.
AU - Mannstadt, Michael
AU - Rejnmark, Lars
AU - Khan, Aliya A.
AU - Guyatt, Gordon
N1 - Funding Information:
We acknowledge unrestricted financial support from: Amolyt, Ascendis, Calcilytix and Takeda. They had no input into the planning or design of the project, the conduct of the reviews, evaluation of the data, writing or review of the manuscript, its content, or conclusions.
Funding Information:
AAK: Speaker for Amgen, Shire/Takeda, Ultragenyx, Alexion, Chugai; grants from Alexion, Amgen, Amolyt, Ascendis, Chugai, Radius, Takeda, Ultragenyx; consultant for Alexion, Amgen, Amolyt, Ascendis, Chugai, Radius, Takeda, Ultragenyx. JPB: Consultant for Amgen, Radius, Ascendis, Calcilytix, Takeda, Amolyt, Rani Therapeutics, MBX, Novo‐Nordisk, Ipsen. MLB has received honoraria from Amgen, Bruno Farmaceutici, Calcilytix, Kyowa Kirin, UCB; grants and/or speaker: Abiogen, Alexion, Amgen, Bruno Farmaceutici, Echolight, Eli Lilly, Kyowa Kirin, SPA, Theramex, UCB; consultant: Alexion, Amolyt, Bruno Farmaceutici, Calcilytix, Kyowa Kirin, UCB. BLC: Consultant for Takeda/Shire, Amolyt Pharma, Calcilytix; grants from Takeda/Shire, Ascendis. LR: Speaker for Amgen, Lilly, Takeda, Alexion, Kyowa Kirin, Amolyt, Ascendis, Ultragenyx; Consultant for Amgen, Lilly, Takeda, Alexion, Kyowa Kirin, Amolyt, Ascendis, Ultragenyx; Grants from Takeda and Kyowa Kirin. MM: Consultant for Takeda, Amolyt, and Chugai; Grants from Takeda and Chugai.
Publisher Copyright:
© 2022 American Society for Bone and Mineral Research (ASBMR).
PY - 2022/12
Y1 - 2022/12
N2 - The complications and symptoms of hypoparathyroidism remain incompletely defined. Measuring serum parathyroid hormone (PTH) and calcium levels early after total thyroidectomy may predict the development of chronic hypoparathyroidism. The study aimed (i) to identify symptoms and complications associated with chronic hypoparathyroidism and determine the prevalence of those symptoms and complications (Part I), and (ii) to examine the utility of early postoperative measurements of PTH and calcium in predicting chronic hypoparathyroidism (Part II). We searched Medline, Medline In-Process, EMBASE, and Cochrane CENTRAL to identify complications and symptoms associated with chronic hypoparathyroidism. We used two predefined criteria (at least three studies reported the complication and symptom and had statistically significantly greater pooled relative estimates). To estimate prevalence, we used the median and interquartile range (IQR) of the studies reporting complications and symptoms. For testing the predictive values of early postoperative measurements of PTH and calcium, we used a bivariate model to perform diagnostic test meta-analysis. In Part I, the 93 eligible studies enrolled a total of 18,973 patients and reported on 170 complications and symptoms. We identified nine most common complications or symptoms probably associated with chronic hypoparathyroidism. The complications or symptoms and the prevalence are as follows: nephrocalcinosis/nephrolithiasis (median prevalence among all studies 15%), renal insufficiency (12%), cataract (17%), seizures (11%), arrhythmia (7%), ischemic heart disease (7%), depression (9%), infection (11%), and all-cause mortality (6%). In Part II, 18 studies with 4325 patients proved eligible. For PTH measurement, regarding the posttest probability, PTH values above 10 pg/mL 12–24 hours postsurgery virtually exclude chronic hypoparathyroidism irrespective of pretest probability (100%). When PTH values are below 10 pg/mL, posttest probabilities range from 3% to 64%. Nine complications and symptoms are probably associated with chronic hypoparathyroidism. A PTH value above a threshold of 10 pg/mL 12–24 hours after total thyroidectomy is a strong predictor that the patients will not develop chronic hypoparathyroidism. Patients with PTH values below the threshold need careful monitoring as some will develop chronic hypoparathyroidism.
AB - The complications and symptoms of hypoparathyroidism remain incompletely defined. Measuring serum parathyroid hormone (PTH) and calcium levels early after total thyroidectomy may predict the development of chronic hypoparathyroidism. The study aimed (i) to identify symptoms and complications associated with chronic hypoparathyroidism and determine the prevalence of those symptoms and complications (Part I), and (ii) to examine the utility of early postoperative measurements of PTH and calcium in predicting chronic hypoparathyroidism (Part II). We searched Medline, Medline In-Process, EMBASE, and Cochrane CENTRAL to identify complications and symptoms associated with chronic hypoparathyroidism. We used two predefined criteria (at least three studies reported the complication and symptom and had statistically significantly greater pooled relative estimates). To estimate prevalence, we used the median and interquartile range (IQR) of the studies reporting complications and symptoms. For testing the predictive values of early postoperative measurements of PTH and calcium, we used a bivariate model to perform diagnostic test meta-analysis. In Part I, the 93 eligible studies enrolled a total of 18,973 patients and reported on 170 complications and symptoms. We identified nine most common complications or symptoms probably associated with chronic hypoparathyroidism. The complications or symptoms and the prevalence are as follows: nephrocalcinosis/nephrolithiasis (median prevalence among all studies 15%), renal insufficiency (12%), cataract (17%), seizures (11%), arrhythmia (7%), ischemic heart disease (7%), depression (9%), infection (11%), and all-cause mortality (6%). In Part II, 18 studies with 4325 patients proved eligible. For PTH measurement, regarding the posttest probability, PTH values above 10 pg/mL 12–24 hours postsurgery virtually exclude chronic hypoparathyroidism irrespective of pretest probability (100%). When PTH values are below 10 pg/mL, posttest probabilities range from 3% to 64%. Nine complications and symptoms are probably associated with chronic hypoparathyroidism. A PTH value above a threshold of 10 pg/mL 12–24 hours after total thyroidectomy is a strong predictor that the patients will not develop chronic hypoparathyroidism. Patients with PTH values below the threshold need careful monitoring as some will develop chronic hypoparathyroidism.
KW - ASSOCIATION STUDIES
KW - DISORDERS OF CALCIUM/PHOSPHATE METABOLISM
KW - EPIDEMIOLOGY
KW - GENETIC RESEARCH
KW - HUMAN
KW - HYPOPARATHYROIDISM
KW - PARATHYROID-RELATED DISORDERS
UR - http://www.scopus.com/inward/record.url?scp=85142178795&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85142178795&partnerID=8YFLogxK
U2 - 10.1002/jbmr.4673
DO - 10.1002/jbmr.4673
M3 - Article
C2 - 36375810
AN - SCOPUS:85142178795
SN - 0884-0431
VL - 37
SP - 2642
EP - 2653
JO - Journal of Bone and Mineral Research
JF - Journal of Bone and Mineral Research
IS - 12
ER -